[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
There is growing evidence that aldosterone plays an important role in the development of endorgan-damage e.g. vascular and cardiac fibrosis, remodeling and endothelial dysfunction. Aldosterone-antagonism has become a novel therapeutic principle beyond its sodium retention properties in the treatment of cardiovascular diseases. In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation. A new selective aldosterone antagonist, eplerenone, was effective in patients with left ventricular dysfunction after myocardial infarction added to optimal medical therapy.
Kolloch
R
R
Medizinische Klinik, Krankenanstalten Gilead, Bielefeld. Kolloch@gilead.de
Offers
E
E
D000450:Aldosterone / Q000502:physiology; D002986:Clinical Trials as Topic; D000077545:Eplerenone; D005858:Germany; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone